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Abstract
Early-onset epileptic encephalopathy (EE) and combined developmental and epileptic encephalopathies (DEE) are clinically
and genetically heterogeneous severely devastating conditions. Recent studies emphasized de novo variants as major
underlying cause suggesting a generally low-recurrence risk. In order to better understand the full genetic landscape of EE
and DEE, we performed high-resolution chromosomal microarray analysis in combination with whole-exome sequencing in
63 deeply phenotyped independent patients. After bioinformatic ﬁltering for rare variants, diagnostic yield was improved for
recessive disorders by manual data curation as well as molecular modeling of missense variants and untargeted plasma-
metabolomics in selected patients. In total, we yielded a diagnosis in ∼42% of cases with causative copy number variants in
6 patients (∼10%) and causative sequence variants in 16 established disease genes in 20 patients (∼32%), including
compound heterozygosity for causative sequence and copy number variants in one patient. In total, 38% of diagnosed cases
were caused by recessive genes, of which two cases escaped automatic calling due to one allele occurring de novo. Notably,
we found the recessive gene SPATA5 causative in as much as 3% of our cohort, indicating that it may have been
underdiagnosed in previous studies. We further support candidacy for neurodevelopmental disorders of four previously
described genes (PIK3AP1, GTF3C3, UFC1, and WRAP53), three of which also followed a recessive inheritance pattern.
Our results therefore conﬁrm the importance of de novo causative gene variants in EE/DEE, but additionally illustrate the
major role of mostly compound heterozygous or hemizygous recessive inheritance and consequently high-recurrence risk.
Introduction
The term epileptic encephalopathy (EE) denotes a rare
group of severe, early-onset epilepsies that tend to be
pharmacoresistant with generally poor outcome and often
severe intellectual disability [1]. EEs are heterogeneous
with respect to seizure semiology and neurological comor-
bidities and encompass several clinical entities, such as
Dravet- (MIM 607208), Ohtahara- (MIM 308350), and
West syndromes (MIM 308350). They have been long
thought to be acquired rather than genetic, given their
common occurrence in a single individual with no family
history [2]. Advances in genomic technologies over the past
decade have unraveled a variety of genetic causes of epi-
leptic encephalopathies and indicated that in some of these
genetic entities intellectual disability or autism may be a
primary clinical sign independent of the presence of epi-
lepsy [1, 2]. These observations resulted in the new
recommendation in 2017 to refer to EE only where “the
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abundant epileptiform activity interferes with development
resulting in cognitive slowing and often regression” and
“developmental and epileptic encephalopathy” (DEE)
where there is additional developmental impairment inde-
pendent of the epileptic activity [3].
Despite the growing number of known EE/DEE disease
genes, the majority of patients still remain without etiolo-
gical diagnosis. A retrospective, single-center cohort study
evidenced that clinical signs, MRI, and targeted metabolic
tests lead to an etiological diagnosis in about 13% of
patients with “epileptic encephalopathy” [4]. In patients
with a clinically unrecognized etiology (likely) causative de
novo copy number variants (CNVs) accounted for about 3–
10% of patients in several studies [4–8]. A large whole-
exome sequencing study in “epileptic encephalopathy”
patients established de novo variants, as disease cause in
12% [9]. This ﬁnding was further supported by gene panel
and whole-genome sequencing studies which, considering
those with a minimum of 50 patients, revealed a diagnostic
yield of up to 37 and 32%, respectively, again with the vast
majority of disease-associated variants occurring as de novo
events [4, 10–17]. However, a recent report on diagnostic
exome sequencing in 89 unselected patients with “epileptic
encephalopathy” yielded a diagnosis in ∼43% cases,
including ∼10% with recessive inheritance [18]. In order to
further evaluate the etiology and the role of recessive
inheritance in EE/DEE, we performed a comprehensive
single-center study to unravel the underlying etiology in 63
deeply phenotyped patients with early-onset EE or DEE of
clinically unrecognized etiology by combining whole-
exome sequencing and high-resolution chromosomal CNV
studies.
Subjects and methods
Patients
After approval of this single-center study by the ethical
committee of the Kanton of Zurich and following informed
consent by the participating individuals or their legal
guardians, patients, available parents, and selected further
family members were enrolled from 2013–2015 if the
patients fulﬁlled the following inclusion criteria: (1)
developmental delay and onset of epilepsy below the age of
4.5 years (in order to encompass early-infantile, infantile,
and early childhood-onset epilepsy), (2) pharmacoresistance
for at least 6 months (reﬂecting the common deﬁnition of
pharmacoresistance as ongoing seizures after trial of two
different drugs and the time needed to try two anti-
epileptics), (3) no persistent spike wave focus in EEG
(because they may indicate localized cortical dysplasia
which is not yet detectable on early MR images as a distinct
etiological clue), (4) absence of speciﬁc malformations on
cerebral MRI, and (5) unknown etiology after standard
clinical evaluation including an extended targeted metabolic
screening (B6 vitamers, amino acids, and pipecolic acid in
the plasma, alpha-aminoadipic semialdehyde and organic
acids in urine). All patients were seen by experienced
neuropediatricians and medical geneticists and deeply
phenotyped including clinical and family history, physical
examination and analysis of seizure semiology, and EEG
ﬁndings.
Chromosomal microarray analysis (CMA)
After extraction of genomic DNA from peripheral blood
samples, high-resolution chromosomal microarray studies
were performed using Affymetrix Cytoscan HD arrays
(containing about 750,000 genotype-able SNPs and 1.9
million non-polymorphic probes) (Affymetrix, Santa Clara,
CA, USA), as previously described [19]. The analyses were
primarily performed in patients only, followed by parental
testing in case of (likely) causative or unclear ﬁndings in the
patient. Rare CNVs not present in in-house and Affymetrix
healthy control samples as well as CNVs overlapping
recurrent disease loci underwent visual assessment of the
actual marker location and distribution, and these were
further investigated for their clinical relevance using the
following databases: DECIPHER (https://decipher.sanger.
ac.uk/), ISCA consortium (https://www.iscaconsortium.org/),
OMIM (Online Mendelian Inheritance in Man,
https://www.omim.org/), UCSC genome browser (http://
genome.ucsc.edu/), and PubMed (http://www.ncbi.nlm.nih.
gov/pubmed). De novo CNVs were conﬁrmed by alter-
native methods when their conﬁdence score or marker
content did not allow reliable calling of the CNV by array
data alone. All detected rare CNVs were submitted to the
DECIPHER database [20].
Whole-exome sequencing and further studies
Whole-exome sequencing was performed using the Agilent
SureSelectXT Clinical Research Exome Kit (V5 CRE)
(Agilent Technologies, Santa Clara, CA, USA) for captur-
ing, followed by paired-end sequencing of 125 bp forward
and 125 bp reverse using a HiSeq SBS Kit v4 on a
HiSeq2500 System (Illumina, San Diego, CA, USA). To
achieve a high average coverage, only 12–15 samples were
pooled within four lanes. Raw fastQ ﬁles were aligned to
the hg19 reference genome using the NextGENe software
(SoftGenetics, State College, PA, USA). Average sequen-
cing coverage was 212-fold with > 96% of the region-of-
interest covered at least 20-fold. Variants were called if
observed in at least 16% of reads with sufﬁcient quality
level. The resulting variants were annotated for potential
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damaging effects by standard in silico prediction tools, such
as SIFT (http://sift.jcvi.org/), PolyPhen2 (http://genetics.bw
h.harvard.edu/pph2/), LRT, MutationTaster (http://www.
mutationtaster.org), MutationAssessor, FATHMM, GERP,
and CADD (http://cadd.gs.washington.edu/), as provided
within the NextGENe software. The ALAMUT visual
prediction software version 2.7.2 (Interactive Biosoftware,
Rouen, France) was used for additional exploration in
selected variants. Rare protein changing variants and splice
site variants (including 12 intronic basepairs) with an
overall minor allele frequency below 2% were analyzed for
de novo, compound heterozygous, and homozygous calls,
and additionally for inherited X-chromosomal calls in boys,
and visually inspected for veriﬁcation of the assumed
inheritance pattern. Resulting genes with potentially
damaging variants were manually assessed for known or
suspected association with EE or overlapping neurodeve-
lopmental disorders using a variety of databases, such as
ClinVar, DECIPHER, Exome Aggregation Consortium
(ExAC, http://exac.broadinstitute.org/), HGMD (Human
Genome Mutation Database, http://www.hgmd.org/), ISCA
consortium, OMIM, UCSC genome browser, PubMed,
Simons Foundation SFARI database (https://gene.sfari.org/),
and SysID database (http://sysid.cmbi.umcn.nl/). All de
novo variants, diagnostic and candidate disease variants
were conﬁrmed by Sanger sequencing and discussed within
the team, including natural scientists, clinical geneticists,
and neuropediatricians. In selected candidate missense
variants, potential functional effects were further evaluated
by structural mutation modeling. In patients with unavail-
ability of one parent, in-silico designed ﬁlters for genes
known to be associated with intellectual disability or epi-
lepsy were used. Independently, all variants were ﬁltered for
overlap with speciﬁc variants described in the Human
Genome Mutation Database, for inherited variants in known
intellectual disability/epilepsy genes unreported at the time
of analysis, and for loss-of-function variants in genes of the
Human Genome Mutation Database. Classiﬁcation of
potentially deleterious variants in known disease genes
followed the ACMG guidelines [21]. From the ExAC
database, only variants that passed the quality ﬁlters were
considered. In selected cases with only one disease-
associated sequence or copy number variant in recessive
disease genes, sequencing gaps were covered by Sanger
sequencing. In selected cases with X-chromosomal variants
potentially affecting function, X-inactivation ratios were
tested as described by Lau et al. [22]. In selected cases with
variants of unclear signiﬁcance in splice sites or with
monoallelic disease-associated variants in recessive disease
genes RNA was extracted from blood samples using the
PAXgene Blood System (PreAnalytiX, Hombrechtikon,
Switzerland) and transcribed into cDNA using Superscript
III Reverse Transcriptase and random hexamers (Invitrogen/
ThermoFisher Scientiﬁc, Waltham, MA, USA) and used for
PCR ampliﬁcations and Sanger sequencing, respectively.
All EE-associated and candidate variants were submitted to
the LOVD [23] (Leiden Open Variation Database) acces-
sible at www.LOVD.nl/ followed by the respective gene
name, e.g., www.LOVD.nl/SPATA5 database. The
respective LOVD patient IDs are given in Table 3 and the
Supplementary Tables.
In plasma samples of three patients with ﬁndings from
exome sequencing that indicated disturbance of metabolic
pathways, we performed an untargeted metabolomic screen
as previously described [24, 25].
Results
Patient characteristics
We recruited a total of 63 independent, mostly sporadic
index cases with EE (n= 42; 67%) or DEE (n= 21; 33%).
Five (8%) had affected siblings: two had a likewise affected
monozygotic twin, and three had one or two likewise
affected siblings. Parents of four index cases (6%) were
consanguineous (three sporadic and one patient with
affected siblings). In all but two families in whom the
fathers were not available, DNA samples of both parents
could be collected. Index cases comprised 38 males and 25
females. The median age of seizure onset was 7 months
(range 1 month to 4 3/12 years). The median age at last
investigation of index patients was 7 years (range 6 months
to 38 years). Four patients (6%) deceased during the study.
The 58 patients for whom detailed information was avail-
able took on average 5.6 different antiepileptic drugs over
the course of their disease. Neurodevelopmental character-
istics of the cohort are summarized in Table 1 and detailed
phenotypic information is provided in Table S1 in the
Supplementary Material.
Genomic analyses
Chromosomal microarray analysis revealed a total of 50
reliably called rare coding and recurrent disease loci CNVs
in 33 (52%) of index patients sizing 7–7700 kb with a
median size of 110 kb and a maximum number of three per
patient (Table S2 in the Supplementary Material). Six of the
nine de novo CNVs affected well-known disease loci
(∼10% of the cohort) (Fig. 1a and Tables 2–3 and Tables S2
and S3 in the Supplementary Material). Five of the latter
established a diagnosis unequivocally explaining the EE/
DEE phenotype, but we cannot exclude further contributing
factors to pathogenicity in the de novo 2Mb duplication of
the chromosomal region 22q11.22–22q11.23 (MIM
608363) representing a recurrent CNV between the low
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copy repeats LCR22-E and LCR22-H causing a variable
neurodevelopmental phenotype with reduced penetrance
[26]. Four of the inherited heterozygous deletions affected
known recessive disease genes, of which two, FARS2 (MIM
611592) and SPATA5 (MIM 613940), have been associated
with neurodevelopmental disorders. Notably, one male and
two female patients (5%) without deﬁnite diagnosis har-
bored the recurrent Xp22.31 duplication or triplication of
1.7 Mb including the STS (MIM 300747) locus, which has
been discussed as a risk factor for neurodevelopmental
disease and epilepsy in both sexes [27–29]. In our Affy-
metrix European and American healthy control cohort, the
duplication was found in three females out of 1038 indivi-
duals indicating a population prevalence of 0.3%, which is
similar to that found in a previous study [29]. While the
latter study found no signiﬁcant difference between 20,095
various clinical cases and 5088 controls, the frequency of
copy number gains at the STS locus was signiﬁcantly
increased in our epileptic encephalopathy cohort (p <
0.0001, Chi-Square two-sided test). We therefore analyzed
further available members in two families, which indicated
no segregation of the duplication with the phenotype, but
left the clinical relevance of the triplication open (Supple-
mental Figure S1 and Table S2 in the Supplementary
Material).
Whole-exome sequencing was performed in 60 patients,
one sibling and 104 parents. Three of the ﬁve patients with
a de novo CNV fully explaining the phenotype were not
exome sequenced. In nine patients, only the index cases
were exome sequenced and since a ﬁnal diagnosis could be
already reached in eight of these, parental samples were
only used for segregation analysis by Sanger sequencing.
Since only one patient in whom trio-sequencing was not
possible due to lack of parental samples remained without
diagnosis, this approach did not affect diagnostic yield
statistics. In the 51 trios who underwent whole-exome
sequencing in the patients and both parents we identiﬁed
per patient a median of one de novo, one homozygous,
seven compound heterozygous, and nine X-linked inherited
rare variants (Fig. 1b). In 20 patients, disease-associated
variants in established EE/DEE genes were identiﬁed
establishing an etiological diagnosis in 32% of the total
cohort (Fig. 1c, d, Table 3, Tables S3 and S4 in the Sup-
plementary Material). These sequence alterations include
15 novel variants, ﬁrst described in this paper, and occurred
in 14 well-known EE/DEE genes as well as in two disease
genes (GABRB2 [MIM 600232], PRUNE1 [MIM 617413])
previously reported in a few patients only (Table 2 and S3).
Very recently, Hamdan et al. [16] reported 11 patients
harboring de novo missense variants in GABRB2 with
early-onset epilepsy, severe intellectual disability, acquired
microcephaly, hypotonia, and further neurological signs in
the majority of patients. Our patient (ID 73324) harboring a
novel de novo variant c.719 G > C p.(Arg240Thr) in
GABRB2 likely affecting function also shows these com-
mon features (see Table S1 and S3 in the Supplementary
Material).
PRUNE1 was recently described to cause a novel
autosomal recessive disease (MIM 617481) characterized
by severe global developmental delay, microcephaly,
dysmorphic features, muscle tone abnormalities, and
variable brain abnormalities such as delayed myelination,
thin corpus callosum or cerebellar hypoplasia, but several
patients are also reported to have early-onset seizures (see
also Supplementary Table S8) [30]. Our index patient (ID
69937) from consanguineous parents had a severe DEE
phenotype but cerebral MRI showed no malformation but
rather immature cortex differentiation and discrete signs
of hypoxia. He had two brothers with a similar phenotype
that died at the age of 4 m and 2 y 9 m, respectively (see
Table S1 in the Supplementary Material). The homo-
zygous variant in PRUNE1 (NM_021222.2:c.[316 G >
A];[316 G > A] p.[(Asp106Asn)];[(Asp106Asn)]), details
in Table S3 in the Supplementary Material) detected in
Table 1 Summary of main clinical characteristics in 63 index patients
Neurodevelopmental traits Number of patients
(percentage)
Profound intellectual disability 16 (25.3%)
Moderate to severe intellectual
disability
47 (74.6%)
Ataxia 21 (33.3%) (44% of
those who could walk)
Cerebral palsy 31 (49.2%)
Muscular hypotonia 49 (77.8%)
Microcephaly 27 (41.9%)
Macrocephaly 4 (6.3%)
Single seizure type 6 (9.5%)
Multiple seizure types 57 (90.5%)
Status epilepticus 13 (20.6%)
Seizure Semiology
Epileptic spasms 20 (31.8%)
Generalized/focal tonic seizures 36 (57%)
Generalized/focal clonic seizures 10 (15.9%)
Generalized tonic-clonic seizures 33 (52.4%)
Generalized/focal myoclonic
seizures
31 (49.2%)
Atonic seizures 15 (42.9%)
Myoclonic-atonic seizures 5 (7.9%)
Focal seizures aware 19 (30.2%)
Focal seizures with impaired
awareness
17 (26.9%)
Early-onset absences 10 (15.9%)
Atypical absences 7 (11.1%)
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our patient and his available affected brother is the same
sequence variant that was already reported as disease-
associated in two families by Karaca et al. [30].
In two index patients and one affected brother with
variants of unclear signiﬁcance in established disease genes
affecting metabolic pathways, we were able to conﬁrm
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pathogenicity by untargeted metabolomic analyses. In
monozygotic twin brothers (ID 72555 and 72719) carrying
a missense variant in the X-linked spermine synthase gene
(SMS, MIM 300105) related to Snyder–Robinson syn-
drome, we found signiﬁcantly increased N8-
acetylspermidine in plasma, a metabolite that accumulates
upstream to the enzyme defect [25]. In a female patient (ID
69986) with two novel inherited compound, heterozygous
variants in the aconitase 2 gene (ACO2, MIM 100850)
plasma metabolomic analysis distinguished a metabolic
ﬁngerprint proﬁle that reﬂects the enzyme deﬁciency within
the citric acid cycle but also perturbations in associated
metabolic pathways [24].
Additionally, we searched for secondary ﬁndings in the
exome sequencing data and hereby identiﬁed 56 speciﬁcally
reported disease alleles or loss-of-function or unreported
variants in Human Genome Mutation Database genes not
related to EE and reclassiﬁed them manually (Fig. 1e and
Table 3 and S7 of the Supplementary Material). An over-
view of primary and secondary ﬁndings, as well as variants
in candidate genes is provided in Table S8 of the Supple-
mentary Material.
Discussion
Applying high-resolution chromosomal copy number pro-
ﬁling and whole-exome sequencing in 63 index cases with
EE/DEE and the majority of their healthy parents estab-
lished a diagnosis in ∼42% of patients. De novo CNVs
accounted for ∼10% of the diagnostic yield, which is higher
than the 3–5% reported in most of previous studies [4–7],
but is in line with a recent report on copy number proﬁling
from exome sequencing data [8] and may be explained by
the higher genome-wide resolution for CNV detection of
our high-resolution chromosomal microarray analysis in
comparison with the lower-resolution microarrays and
exome sequencing data previously used. Although CNVs
might be identiﬁed by read-depth analysis from exome
sequencing data with a similar diagnostic yield as by high-
resolution microarrays, high-resolution copy-number pro-
ﬁling from exome data requires signiﬁcantly more con-
ﬁrmatory work-up owing to their lower speciﬁcity [31]. Our
∼32% diagnostic yield achieved by whole-exome sequen-
cing is within the range published by previous studies, but
due to varying pretesting, patient inclusion criteria and
cohort compositions direct comparison is difﬁcult [4, 9–16,
18, 32–34]. Nevertheless, with respect to our ∼16% diag-
nostic yield from causative de novo sequence variants,
which comprise the vast majority in the latter studies, we
found the same spectrum of affected genes. As a major
difference, however, we additionally found (likely) disease-
associated variants in autosomal and X-linked recessive
genes in another ∼16% of index patients. This ﬁnding is not
explained by consanguinity, since only one of ten of these
index patients is an offspring of a consanguineous couple.
There is also neither a difference in the ratio of EE/DEE
diagnoses and age of onset of seizures, nor any other
apparent clinical difference between the dominant and
recessive disease group. The only previous report of a
considerable diagnostic yield of 11% for recessive sequence
variants so far was a diagnostic whole-exome sequencing
study with limited clinical data [18]. Given the high number
of rare inherited variants per patient (Fig. 1b), identiﬁcation
of causative inherited pathogenic variants is much more
challenging than the evaluation of de novo variants, and in
our study required extensive manual data annotation
including interdisciplinary clinical assessment, a compre-
hensive search for second hits in single-recessive variants as
well as functional evidence for pathogenicity of missense
variants derived from structural mutation modeling and
untargeted metabolome data. Notably, metabolomic analy-
sis increased our diagnostic yield for recessive disease
genes by supporting the pathogenicity of missense variants
involved in metabolic pathways, as illustrated for Snyder
Robinson syndrome and ACO2 deﬁciency [24, 25]. More-
over, in three cases with biallelic disease-associated variants
in known autosomal recessive disease genes, only manual
curation unraveled the respective second variant. In these
three cases, there was a single-inherited sequence variant in
trans with either a de novo sequence or an inherited copy
number variant each (Fig. 2). Accordingly, the single-
inherited sequence variants were initially ﬁltered out by
standard algorithms, since compound heterozygosity is
commonly deﬁned as two variants occurring at different
genomic positions within the same gene with one variant
inherited from each heterozygous parent [35]. As no pre-
vious study considered copy-number and sequence variants
for compound heterozygous hits, such allele constellations
were not called by ﬁltering strategies reported so far.
Without these three challenging cases, our diagnostic yield
Fig. 1 Summary of genetic ﬁndings. a Percentage of patients with ≥ 1
de novo or inherited rare copy number variants and their respective
classiﬁcation of clinical relevance. b Total numbers, and medians,
minimum and maximum numbers per patients of variants following
the respective modes of inheritance identiﬁed by whole-exome
sequencing in 51 child–parent trios. c Percentage of patients with
(likely) disease-associated CNV or SV ﬁndings in established EE
genes or with potentially disease-causing candidate genes. d Dis-
tribution of inheritance modes in diagnosed patients with (likely) EE-
associated CNV or SV in established disease genes. e Results of (re-)
classiﬁcation of 56 secondary ﬁndings from whole-exome sequencing,
of which 16% represented carriership of single alleles of recessive
disorders and 12% indicated mainly dominant disease alleles as sec-
ondary ﬁndings. CNV copy number variant, SV sequence variant,
VOUS variants of unknown clinical signiﬁcance, XL dom. X-linked
dominant, XL rec. inh. X-linked recessive inherited
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for recessive disease genes would be in the same range as
reported by Helbig et al. [18]. These unexpected mechan-
isms may also explain why we found SPATA5, which was
rarely reported so far [36–40], as a more common cause of
EE/DEE (2/63; 3%). In order to independently prove this
high frequency of SPATA5-related EE and DEE, we ana-
lyzed its prevalence in 39 cases with infantile or childhood
epilepsies who received diagnostic exome sequencing and
identiﬁed one case carrying a previously reported homo-
zygous SPATA5 disease-associated variant NM_145207.2
(SPATA5):c.[251 G > A];[251 G > A] p.[(Arg84Gln)];
[(Arg84Gln)]. This diagnostic case with developmental
encephalopathy with late-onset epilepsy also had an unusual
mutational mechanism with homozygotization of a mater-
nally inherited variant due to maternal isodisomy of chro-
mosome 4. Thus, our overall ﬁnding of 3 out of 102
combined research and diagnostic patients carrying causa-
tive biallelic variants indicates that SPATA5 is a frequent
cause of developmental epileptic disorders accounting for
3% of cases (Table 4). Notably, in a recently published
whole-exome sequencing study of 320 patient–parent trios
with EE a single patient with compound heterozygous
SPATA5 pathogenic variants was the only case with auto-
somal recessive disease cause found [33].
Concerning the broad variant ﬁltering applied (minor
allele frequency (MAF) < 2%,+ /−12 ﬂanking intronic bp,
16% aberrant allele frequency), our ﬁndings of three EE-
associated variants within three to six ﬂanking intronic
basepairs indicate the importance of evaluation of the spli-
cing region beyond the canonical splice site. However, the
highest European MAF observed amongst our EE-
associated variants was 0.03% (SPATA5 rs748291365) for
recessive disease genes, and one de novo variant (SCN8A
rs796053229) had a MAF of 0.003% in the Latino popu-
lation and an overall MAF of 0.0004% in gnomAD. With
reference to the aberrant allele frequency, the lowest
observed in our cohort was 32% in apparently heterozygous
inherited disease-associated variants, but we did not identify
a de novo variant below this value indicative of a mosaic
status.
It is also noteworthy that our ﬁndings further support the
disease association of the two recently established disease
genes GABRB2 and PRUNE1, as well as the candidacy of
PIK3AP1, GTF3C3, WRAP53, and UFC1 as potential
neurodevelopmental disease genes (see Table S5 in the
Supplementary Material). To date, only two de novo mis-
sense variants in PIK3AP1 have been reported in two
independent patients with infantile spasms [41]. Our patient
harbors an unreported de novo missense variant with dele-
terious predictions in the DBB domain, which is required in
other proteins to mediate protein–protein interaction. Fur-
ther reports and functional studies are needed to evaluate the
potential role of this gene in neurodevelopmental disorders.
GTF3C3 was classiﬁed as moderately conﬁdent candi-
date gene in a recently published study on neurodevelop-
mental disorders in consanguineous families after detection
of homozygous missense variants in two affected sisters
with a phenotype including mild ID, seizures, and dys-
morphism [42]. Another study reported a patient with pro-
found microcephaly, facial dysmorphism, and failure to
thrive to harbor a homozygous splice site variant in
GTF3C3 causing skipping of exon 10 and parts of exon 11
(in-frame deletion) [43]. Furthermore, the yeast ortholog of
GTF3C3, Tfc4, has been shown to interact with BRF1 to
regulate RNA polymerase III-mediated transcription [44,
45]. Biallelic variants in BRF1 (MIM 604902) cause the
cerebellofaciodental syndrome (MIM 616202) with a
similar phenotype as our patient (delayed development,
intellectual disability, abnormal facial and dental ﬁndings,
and cerebellar hypoplasia) [46, 47]. Thus, we consider
GTF3C3 as a candidate for neurodevelopmental disorders
which may or may not include epilepsy.
Table 2 Summary of established
genes causing EE/DEE in our
study cohort, as well as recurrent
candidate genes for
neurodevelopmental disorders
Disease gene category Mode of inheritance
Autosomal X-linked
Dominant Recessive Dominant Recessive
(de novo) (inherited or otherwise indicated) (de novo) (inherited)
Established genes/regions 1p36 deletion ACO2 CH CDKL5 deletion ARX
22q11.2 duplication AP4S1 HO CDKL5 SMS
KCNQ2 BRAT1 CH
MBD5 deletion POLG CH
SCN1A (3 × ) SPATA5 CH (one allele deletion)
SCN2A SPATA5 CH (de novo and inherited)
SCN8A SZT2 CH (de novo and inherited)
STXBP1 (2 × ) PRUNE1 HO
UBE3A deletion (2 × )
GABRB2
Recurrent candidate genes PIK3AP1 GTF3C3 CH
UFC1 HO
WRAP53 CH
CH compound heterozygous, HO homozygous
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Autosomal-recessive variants in WRAP53 have been
reported as disease cause in two unrelated patients with the
classical phenotype of Dyskeratosis congenita (DC) (MIM
613988) [48], supported by functional studies of the detected
variants [48]. Our patient harbors two variants in compound-
heterozygous constellation, NM_018081.2:c.[1034 A >G];
[1303 G >A] p.[(Tyr345Cys)];[[(Gly435Arg)] (see Table S5
in the Supplementary Material), of which the ﬁrst is novel and
the latter has been reported and functionally studied by Zhong
et al. [48]. As previously described in other DC subtypes [49],
our 2 ½ year-old patient shows delayed development,
intrauterine growth retardation, cerebellar hypoplasia, micro-
cephaly, sparse ﬁne hair, and bone marrow failure, but does
not yet present classical signs of variable age of onset, such as
nails dysplasia, abnormal pigmentation, and oral leukoplakia.
Additionally, our patient has early onset and therapy resistant
absence seizures, which is in line with ﬁndings in a DC
mouse model [50], but this expansion of the phenotype needs
conﬁrmation by further observations.
UFC1 was ﬁrst proposed as a candidate gene for reces-
sive ID after the detection of a homozygous missense var-
iant in two siblings with global developmental delay and
microcephaly by Anazi et al. [51]. A collaborative effort on
this gene revealed in addition to our patient with a homo-
zygous missense variant further ﬁve patients from two
families harboring a distinct homozygous variant, all shar-
ing a phenotype of early-onset encephalopathy (micro-
cephaly, short stature, global developmental delay, seizures,
failure to thrive). This cohort was recently published along
with evidence for a hypomorphic effect of both missense
Pathogenic de novo variant c.2389C>G
p.(Pro797Ala) on paternal reads
A B
C D E c. 989_991del, p.(Thr330del)
p.[(Met1?)];[(Pro797Ala;Asp829Tyr)]
compound heterozygous
inherited and de novo variants
p.[(Met1?)];[=]
51kb deletion including exons 12 & 13
(c.2080_2213del, p.(Gly694Phefs*23))
p.[(Thr330del)];[(=)]
p.[(Gly694Phefs*23)];[(Thr330del)]
compound heterozygous
copy number and sequence variants
51 kb deletion
p.[(=)];[(Gly694Phefs*23)]
Patient 73068
Patient 47651
Mother
Patient
Father
p.[(=)];[(Asp829Tyr)]
Paternal SNP rs35206443 c.2485G>T
p.(Asp829Tyr)
Patient
Father
Fig. 2 Disease causing biallelic SPATA5 variants in two independent
families demonstrating the value of hypothesis driven manual data
analysis (variant nomenclature and exon numbering according to
NM_145207.2 and NG_051570.1, respectively). a, b Pedigree of
patient 73068 (a) summarizing the segregation of the maternally
inherited variant p.(Met1?) and the de novo variant p.(Pro797Ala) on
the paternal allele; (b) Whole-exome sequencing data of exon 15 in the
patient demonstrating the localization of both, the de novo variant
c.2389 C > G (p.(Pro797Ala)) and the paternally inherited single
nucleotide polymorphism (SNP) rs35206443 (c.2485 G > T, p.
(Asp829Tyr)) on the same allele. c-e Pedigree of patient 47651
illustrating the compound heterozygous constellation of the maternally
inherited, heterozygous 51 kb deletion comprising exon 12 and 13
(c.2080_2213del; p.(Gly694Phefs*23)) detected by high-resolution
chromosomal microarray analysis (d), and the paternally inherited
disease-associated sequence variant c.989_991del (p.(Thr330del))
detected by whole-exome sequencing (e)
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variants in functional studies [52]. Of note, variants in
UBA5 and UFM1 in the same ufmylation pathway have also
been described in patients with early-onset encephalopathy
[52–56].
With respect to genetic counseling, autosomal or X-
linked recessive disorders were identiﬁed in 38% of diag-
nosed cases. Since in two cases with autosomal recessive
variants one allele each occurred as de novo alteration, a
high-recurrence risk of 25% for further siblings was present
in 31% of the diagnosed cases. In contrast to previous
assumptions [2], this high-recurrence risk is not restricted to
offspring of consanguineous parents, which accounted for a
small minority of our cases with recessive inheritance.
Thus, the true recurrence risk may have been under-
estimated due to the low number of pregnancies following
such severely affected patients in the hitherto absence of
prenatal diagnostic options. Accordingly, as a direct result
from the identiﬁcation of the underlying genetic cause, 19%
of all diagnosed families beneﬁted from targeted prenatal
testing during this study. Moreover, the genetic diagnosis
led to a change in epilepsy treatment in 12% of diagnosed
patients. In line with a previous report indicating a higher
diagnostic yield of 39% de novo pathogenic variants in very
early-onset epilepsy (≤2 months) in comparison with seizure
disorders in general (18%) [57], we found a remarkably
high-diagnostic yield of 77% de novo and recessive
pathogenic variants in patients with seizure onset within the
ﬁrst 2 months in comparison with our whole cohort
(∼42%).
We also revealed additional genetic disorders as sec-
ondary ﬁndings in known disease genes in 10% of patients
(Asthenozoospermia, late-onset mild hearing impairment,
predisposition to endocrine tumors and adrenal Cushing
syndrome, Noonan syndrome 5, left ventricular non-
compaction 7, MPO deﬁciency; Supplementary Table S8).
This observation of blended phenotypes is higher than in a
broader clinical exome sequencing study [58], but similar to
the results of a whole-exome sequencing study in patients
with combined phenotypes of metabolic and intellectual
developmental disorders [59].
In conclusion, we found evidence of causative copy
number and sequence variants in established disease genes
explaining together with recurrent candidate genes about
48% of patients with EE/DEE with an unexpected high
contribution of inherited recessive disorders, which is nei-
ther explained by founder mutations nor by consanguinity,
imposing a signiﬁcant recurrence risk even in outbred
populations.
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